SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+8.92%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$311M
AUM Growth
+$311M
(-0.8%)
Cap. Flow
-$5.24M
Cap. Flow
% of AUM
-1.69%
Top 10 Holdings %
Top 10 Hldgs %
50.16%
Holding
74
New
18
Increased
16
Reduced
15
Closed
20
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$13M |
| 2 |
Legend Biotech
LEGN
|
$9.59M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$9.03M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$8.83M |
| 5 |
Mineralys Therapeutics
MLYS
|
$8.55M |
Top Sells
| 1 |
Roivant Sciences
ROIV
|
$22.3M |
| 2 |
Revolution Medicines
RVMD
|
$11.3M |
| 3 |
Nuvalent
NUVL
|
$9.96M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$9.21M |
| 5 |
CG Oncology
CGON
|
$7.1M |
Sector Composition
| 1 | Healthcare | 99.49% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $22.2M | 7.13% | 2,372,634 +774,040 | +48% | +$7.25M |
|
2
Immunovant
IMVT
$2.56B
| $20.8M | 6.68% | 1,300,860 +447,388 | +52% | +$7.16M |
|
3
Scholar Rock
SRRK
$3.14B
| $18.7M | 6% | 528,115 -38,097 | -7% | -$1.35M |
|
|
CNTA
4
Centessa Pharmaceuticals
CNTA
$2.25B
| $16.6M | 5.34% | 1,265,672 +672,337 | +113% | +$8.83M |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $15.9M | 5.12% | 52,694 +11,758 | +29% | +$3.56M |
|
6
Merus
MRUS
$4.98B
| $14M | 4.49% | 266,094 -80,662 | -23% | -$4.24M |
|
7
Arcellx
ACLX
$3.85B
| $13.3M | 4.26% | 201,452 -72,322 | -26% | -$4.76M |
|
|
8
Cidara Therapeutics
CDTX
$1.66B
| $13M | 4.17% | +266,774 | New | +$13M |
|
|
9
Rhythm Pharmaceuticals
RYTM
$6.85B
| $11.2M | 3.58% | 176,752 +142,936 | +423% | +$9.03M |
|
10
Alkermes
ALKS
$4.78B
| $10M | 3.22% | 351,124 +158,772 | +83% | +$4.54M |
|
11
Denali Therapeutics
DNLI
$2.23B
| $9.9M | 3.18% | 707,915 +40,837 | +6% | +$571K |
|
|
12
Legend Biotech
LEGN
$6.41B
| $9.59M | 3.08% | +270,144 | New | +$9.59M |
|
13
Geron
GERN
$893M
| $9.38M | 3.01% | 6,649,244 +5,688,937 | +592% | +$8.02M |
|
14
Zai Lab
ZLAB
$3.68B
| $8.76M | 2.81% | 250,438 +224,017 | +848% | +$7.83M |
|
|
15
Mineralys Therapeutics
MLYS
$1.03B
| $8.55M | 2.74% | +631,586 | New | +$8.55M |
|
16
uniQure
QURE
$896M
| $7.98M | 2.56% | 572,615 -158,424 | -22% | -$2.21M |
|
|
17
Roivant Sciences
ROIV
$8.15B
| $6.78M | 2.18% | 601,781 -1,977,079 | -77% | -$22.3M |
|
18
Akero Therapeutics
AKRO
$3.74B
| $6.23M | 2% | 116,779 -39,406 | -25% | -$2.1M |
|
19
Insmed
INSM
$28.8B
| $6.2M | 1.99% | 61,578 -25,481 | -29% | -$2.56M |
|
20
Surrozen
SRZN
$104M
| $6.14M | 1.97% | 686,539 +445,713 | +185% | +$3.98M |
|
21
Wave Life Sciences
WVE
$1.53B
| $5.85M | 1.88% | 900,338 +810,505 | +902% | +$5.27M |
|
|
LENZ
22
LENZ Therapeutics
LENZ
$1.1B
| $5.39M | 1.73% | +183,912 | New | +$5.39M |
|
|
23
Nuvalent
NUVL
$5.52B
| $4.56M | 1.47% | 59,828 -130,573 | -69% | -$9.96M |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $4.37M | 1.4% | 386,790 -47 | -0% | -$531 |
|
25
VistaGen Therapeutics
VTGN
$102M
| $4.12M | 1.32% | 2,413,254 +46,700 | +2% | +$79.7K |
|